PT-141 (Bremelanotide) for Women: Does It Help Low Libido?

Low sexual desire is among the most common sexual complaints in women, yet until 2019 there was no on-demand pharmaceutical treatment specifically approved for it. Vyleesi (bremelanotide) changed that: it became the first subcutaneous, as-needed option cleared by the FDA for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women^[1]. The underlying molecule — PT-141, a synthetic melanocortin-receptor agonist — acts centrally on the brain's desire circuits rather than on genital blood flow, distinguishing it from every erectile-dysfunction drug on the market. The clinical evidence behind the approval rests on two replicated Phase 3 randomized trials in more than 1,200 premenopausal women. This article focuses specifically on that evidence: what HSDD actually is and who meets criteria, what the RECONNECT trials showed (and how modest the effect sizes honestly are), the side-effect profile every woman should weigh before asking about Vyleesi, and who is — and is not — an appropriate candidate. For a broader look at the molecule itself, see our PT-141 guide.

What is HSDD? The clinical diagnosis behind the approval

Hypoactive sexual desire disorder is defined as persistently or recurrently deficient or absent sexual desire or fantasies that causes marked personal distress or interpersonal difficulty, and that cannot be better explained by another medical, psychiatric, hormonal, or relationship problem. The distress criterion is essential: a woman with naturally low desire who is completely unbothered by it does not meet clinical criteria. HSDD is a disorder of unwanted, distressing low desire — not simply a label for anyone whose libido has declined.

Acquired, generalized HSDD — the specific phenotype bremelanotide is approved for — carries two important qualifiers. Acquired means the low desire developed after a period of normal desire, not a lifelong pattern. Generalized means it occurs across all contexts and partners, not only in one relationship or one specific situation. Both qualifiers narrow the eligible population considerably. Situational or relationship-specific low desire, or desire that has always been low, points toward causes that often respond better to psychological or couples therapy than to pharmacology. The RECONNECT trials enrolled only women meeting these narrowed criteria^[1], which is why the FDA approval is tightly scoped.

How PT-141 (bremelanotide) works in the female brain

Sexual desire is regulated partly by the central melanocortin system — a network of neurons in the hypothalamus and limbic system that uses α-melanocyte-stimulating hormone (α-MSH) and related peptides to modulate motivation and appetitive behaviors^[5]. Bremelanotide is a synthetic cyclic peptide analog of α-MSH that agonizes melanocortin-4 receptors (MC4R) in the central nervous system, reinforcing the neural drive toward sexual motivation. This is a brain-first mechanism: it shifts the desire signal at its source, rather than making the vasculature or genitals more responsive to stimulation.

That central mechanism distinguishes bremelanotide from every other sexual-health drug: PDE5 inhibitors like sildenafil work on penile blood flow, topical estrogens address vaginal atrophy, and testosterone supplementation targets hormonal drivers of desire. Bremelanotide targets the melanocortin desire circuit directly^[5]. The approved formulation, Vyleesi, is a 1.75 mg single-dose autoinjector delivered subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. It is on-demand — not taken daily — and the label caps its use at one dose per 24 hours and no more than eight doses per month, primarily because each dose produces a transient rise in blood pressure^[4].

The RECONNECT trials: Phase 3 evidence and honest effect sizes

Vyleesi's FDA approval rests on two identical, replicated Phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT (studies 301 and 302), reported by Kingsberg and colleagues in Obstetrics & Gynecology in 2019^[1]. The integrated analysis enrolled 1,267 premenopausal women with acquired, generalized HSDD and followed them over a 24-week treatment period.

The co-primary endpoints were the change from baseline in the Female Sexual Function Index (FSFI) desire domain score and the change in a Female Sexual Distress Scale (FSDS) item measuring how much low desire bothered the patient. In the integrated analysis, bremelanotide produced a statistically significant increase in desire score of +0.35 versus placebo (P<.001) and a statistically significant reduction in desire-related distress of −0.33 versus placebo (P<.001). Both individual trials replicated these findings^[1].

What does +0.35 mean in practice? The FSFI desire domain ranges from 1.2 to 6.0. A shift of 0.35 points is statistically significant in a well-powered trial of 1,200+ women — but it is modest in absolute terms. Replicated statistical significance across two independent Phase 3 trials is genuine evidence that the drug works; it is not a drug-company artifact. It means that the realistic expectation for a woman starting Vyleesi is a meaningful improvement in desire and reduced distress — not a dramatic restoration of prior-peak libido. Prespecified subgroup analyses confirmed that the benefit was broadly consistent across age, BMI, relationship status, and baseline severity, with women who had higher baseline distress showing somewhat more pronounced improvement^[6].

Side effects: the honest trade-off every woman should know

Tolerability is the central practical limitation of Vyleesi. The full clinical development safety analysis by Clayton and colleagues (2022) consolidated adverse-event data across trials and extensions^[3]:

• Nausea: The most common adverse effect, occurring in approximately 40% of treated patients. About 13% required anti-nausea medication to manage it; roughly 8% discontinued treatment because of it. Nausea typically begins within an hour of injection and resolves over several hours^[3].
• Flushing and headache: Also frequent, generally mild to moderate in severity^[1].
• Transient blood pressure rise: Each dose produces a brief increase in blood pressure — on the order of a few mmHg systolic — with a small compensatory drop in heart rate, typically resolving within approximately 12 hours^[4]. This is why Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, and why the label limits dosing frequency^[4].
• Focal hyperpigmentation: Approximately 1% of patients develop darkening of the skin, gums, or breast tissue due to the drug's melanocortin activity. This is more likely with frequent dosing and in women with darker baseline skin tone. The darkening does not always resolve after stopping the drug — it may be permanent^[3].

Who is — and is not — a candidate for Vyleesi

Appropriate candidates per the FDA label^[1] are premenopausal women who:

• Have acquired HSDD — desire was normal at some earlier period, not always absent.
• Have generalized HSDD — low desire occurs across all contexts and partners, not only in specific situations.
• Experience marked personal distress about the low desire.
• Do not have uncontrolled hypertension or known cardiovascular disease^[4].
• Are not pregnant (no safety data exist in pregnancy).

Who Vyleesi is NOT for:

• Postmenopausal women: The RECONNECT trials enrolled only premenopausal women. Vyleesi is not FDA-approved for postmenopausal HSDD, and there is no pivotal Phase 3 evidence in this population^[1]. Postmenopausal low desire has distinct hormonal drivers — primarily estrogen decline and androgen changes — that may respond to hormone therapy; bremelanotide has not been proven in this group, and using it would be entirely off-label.
• Women with primarily arousal, orgasm, or pain disorders: Vyleesi addresses the desire/motivation domain only. It has not demonstrated clinically meaningful effects on lubrication, physical arousal, or orgasm in the absence of a concurrent desire problem.
• Women with situational or relationship-specific low desire: "Acquired, generalized" is a strict qualifier. Low desire that occurs only with one partner, or primarily during periods of relationship stress, suggests psychological or relational causes more appropriately addressed without pharmacology.
• Men: Vyleesi is not FDA-approved for men, and no pivotal Phase 3 trial in a male population has been completed^[5]. The gray-market "PT-141" used off-label by men is the same molecule without regulatory oversight or verified dosing.

Vyleesi in context: the two FDA-approved options for HSDD

Vyleesi is one of only two FDA-approved pharmacological treatments for premenopausal HSDD. The other is flibanserin (Addyi), a daily oral agent approved in 2015 that works via 5-HT1A agonism / 5-HT2A antagonism — a mechanistically different approach that modulates serotonin and dopamine pathways rather than melanocortin receptors. A 2025 pharmacotherapy review by Barakeh and colleagues placed both agents in evidence-based context: both are modestly effective for their approved indication, with different tolerability profiles^[7]. Flibanserin requires daily dosing at bedtime and has an alcohol interaction restriction; its main side effects are dizziness and somnolence. Bremelanotide is on-demand and injected, with nausea and transient blood-pressure rises as its key trade-offs. Neither is a dramatic fix; both represent real pharmacological support within a narrowly defined clinical population.

Clinical guidelines generally recommend cognitive behavioral therapy and mindfulness-based sex therapy as first-line treatment for HSDD — addressing psychological, relationship, and contextual contributors before or alongside pharmacology. Both Addyi and Vyleesi are best considered adjuncts rather than standalone solutions, particularly for women who have co-occurring relationship or psychological contributors to their low desire.